Hand-assisted laparoscopic surgery: an emerging technique.

BACKGROUND: Some surgeons are finding that the placement of one hand in the abdomen during laparoscopic procedures returns tactile feedback lost during purely laparoscopic surgery and facilitates dissection, retraction, and control of bleeding. Studies comparing patient postoperative discomfort after laparoscopic and hand-assisted laparoscopic procedures have not found a significant difference. METHODS: This article is a review of the current literature on hand-assisted laparoscopic surgery and of the different hand-assisted devices on the market. Included in the review are opinions of expert laparoscopic surgeons who have used hand-assisted devices. RESULTS: More than 100 hand-assisted laparoscopic procedures have been described in the literature. At least four different companies are involved in hand-assisted laparoscopic devices. Three of these companies currently are Food and Drug Administration (FDA) approved in the United States. CONCLUSIONS: Hand-assisted laparoscopic surgery is not necessary for all laparoscopic procedures. Hand-assisted laparoscopic technique is advantageous for certain procedures and clinical situations such as en bloc resections and removal of solid organ tumors, large colon tumors, and the kidney after donor nephrectomy. This technique offers benefits when a large incision is necessary to complete surgery such an open colon anastomosis.

Cardiac tamponade caused by serous pericardial effusion in patients on extracorporeal membrane oxygenation.

PURPOSE: Extracorporeal membrane oxygenation (ECMO) has been successful in the treatment of critically ill children; however, its use has been accompanied by a broad range of complications. The authors describe the presentation, clinical course, treatment, and outcome of 4 patients on ECMO in whom pericardial tamponade developed caused by a serous effusion. METHODS: A retrospective review of patients placed on ECMO at our institution from 1993 to 1997 was performed. The case histories of 4 patients in whom pericardial tamponade developed caused by a serous effusion were reviewed in detail. RESULTS: The first patient presented with hypotension while on venovenous (VV) ECMO. The hypotension improved with fluid resuscitation. The patient was converted from (VV) to venoarterial (VA) ECMO when hypotension recurred. After a third episode of hypotension, a narrow pulse pressure was noted, and echocardiography results confirmed a pericardial effusion. The diagnosis was recognized earlier in the course of the subsequent 3 patients. All 4 patients were treated with aspiration of serous fluid from the pericardium with an over-the-needle plastic catheter that was left in place. More than 1 aspiration was required in all cases. All 4 patients survived. CONCLUSIONS: The authors have identified a group of ECMO patients with pericardial tamponade caused by serous effusion with good response to treatment. A high index of suspicion and early echocardiography is warranted to confirm the diagnosis in a patient with hypotension on ECMO.

Laparoscopic side-to-side pancreaticojejunostomy (Partington-Rochelle) for chronic pancreatitis.

Intractable pain in chronic pancreatitis has been treated by several different procedures, including resection and drainage, or a combination of the two. We describe the technique of laparoscopic side-to-side pancreaticojejunostomy for chronic pancreatitis in five patients. The procedure is performed using five trocars. Stapling and direct suturing are required. Careful selection of patients is important. Preoperative and intraoperative ultrasound is necessary to assess the dilated pancreatic duct. In one of the five patients, the laparoscopic technique was converted to an open procedure because the preoperative findings were not confirmed at exploration. Four of the five patients are pain-free, with 5- to 30-month follow-up. Laparoscopic pancreaticojejunostomy can be performed safely, and it is a procedure that should be considered in the treatment of appropriate patients with chronic pancreatitis.

Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.

Müllerian inhibiting substance (MIS), an inhibitor of growth and development of the female reproductive ducts in male fetuses, requires precise proteolytic cleavage to yield its biologically active species. Human plasmin is now used to cleave and, thereby, activate immunoaffinity-purified recombinant human MIS at its monobasic arginine-serine site at residues 427-428. To avoid the need for exogenous enzymatic cleavage and to simplify purification, we created an arginine-arginine dibasic cleavage site (MIS RR) using site-directed mutagenesis to change the serine at position 428 (AGC) to an arginine (cGC). The mutant cDNA was then stably transfected into a MIS-responsive ocular melanoma cell line, OM431, followed by cloning for amplified expression to test its biological activity in vitro and in vivo. Media from each clone were assayed for production of MIS RR by a sensitive ELISA for holo-MIS, and high- and low-producing clones were selected for further study. Media from the highest MIS RR producer caused Müllerian duct regression in an organ culture bioassay. Other transfections were done with an empty vector (pcDNAI Neo) or a construct lacking the leader sequence and thus failing to secrete MIS, to serve as controls. The OM431 clones containing the MIS RR mutant were growth inhibited in monolayer culture. The high- and low-producing MIS RR OM431 clones, along with transfected OM431 controls, were injected into the tail veins of immunosuppressed severe combined immunodeficiency mice for in vivo analyses. Four to 6 weeks later, pulmonary metastases were counted in uniformly inflated lungs. OM431 clones containing the more easily cleaved MIS RR displayed a significant dose-dependent reduction in pulmonary metastases when compared to the lungs of animals given injections of OM431 clones containing empty vector, leaderless MIS, or wild-type MIS that requires activation by plasmin cleavage. Since the purification protocol of MIS RR is less complicated than that for wild-type MIS, which requires subsequent enzymatic activation, MIS RR can be used for scale-up production with increased yields for further therapeutic trials against MIS-sensitive tumors.